AnnJi Highlights Patient and Family Forum at KDA 2026 with AJ201 Updates AnnJi Pharmaceutical participated in the KDA 2026 Conference, showcasing their pioneering AJ201 development and hosting a dedicated forum for patients and families.

AnnJi Highlights Patient and Family Forum at KDA 2026 with AJ201 Updates #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

Fast Track Designation Granted for AJ201, a Breakthrough Therapy for Kennedy's Disease AnnJi Pharmaceutical's AJ201 has received Fast Track status from the FDA, marking a significant advancement for treating Kennedy's disease, a rare neuromuscular condition.

Fast Track Designation Granted for AJ201, a Breakthrough Therapy for Kennedy's Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

FDA Grants Fast-Track Status to Groundbreaking Therapy AJ201 for Kennedy's Disease AnnJi Pharmaceutical's AJ201 receives Fast-Track designation from the FDA, marking a significant advancement in treatment for Kennedy's Disease.

FDA Grants Fast-Track Status to Groundbreaking Therapy AJ201 for Kennedy's Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

AnnJi Pharmaceutical Achieves Fast Track Designation for AJ201 Targeting Kennedy's Disease AnnJi Pharmaceutical has been awarded Fast Track Designation from the FDA for AJ201, promising development in treating Kennedy's disease, a rare neuromuscular disorder.

AnnJi Pharmaceutical Achieves Fast Track Designation for AJ201 Targeting Kennedy's Disease #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

FDA Grants Fast Track Designation for AJ201, A Novel Therapy for Kennedy Disease AnnJi Pharmaceutical has received Fast Track designation from the FDA for AJ201, a groundbreaking therapy aimed at treating Kennedy Disease, a rare genetic disorder.

FDA Grants Fast Track Designation for AJ201, A Novel Therapy for Kennedy Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease